Mantle cell lymphoma trials in Canada

In Canada 9 Also abroad 150

9 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
Where
London, Ottawa, Toronto
Age
18 years and over
People
182 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06084936
Phase 1Taking people
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Where
Montreal, Toronto, Vancouver
Age
18 years and over
People
215 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07101328 · EU 2025-524180-20-00
Phase 1Taking people
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
Where
Montreal
Age
18 years and over
People
140 worldwide
Run by
Iksuda Therapeutics Ltd.
See details and how to joinNCT05365659
Phase 1Taking people
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
Where
Calgary, Ottawa, Toronto, Vancouver
Age
1 year and over
People
24
Run by
British Columbia Cancer Agency
See details and how to joinNCT06208735
Phase 2Taking people
Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy
Where
Calgary, Edmonton, Hamilton, Toronto, Vancouver
Age
18 years and over
People
40
Run by
Canadian Cancer Trials Group
See details and how to joinNCT07341191
Phase 1/2Taking people
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Where
Calgary, Edmonton, Québec, Toronto, Vancouver
Age
18 years and over
People
689 worldwide
Run by
BeOne Medicines
See details and how to joinNCT05006716 · EU 2022-502157-33-00
No phaseTaking people
Preliminary Assessment of [18F]BL40 in PET/CT Scans
Where
Vancouver
Age
19 years to 100 years
People
30
Run by
British Columbia Cancer Agency
See details and how to joinNCT06224309
Phase 1/2Taking people
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
Where
Calgary, Montreal, Toronto
Age
18 years and over
People
174 worldwide
Run by
AstraZeneca
See details and how to joinNCT06542250
Phase 2Taking people
DALY II USA/ MB-CART2019.1 for DLBCL
Where
Edmonton, Toronto
Age
18 years and over
People
315 worldwide
Run by
Miltenyi Biomedicine GmbH
See details and how to joinNCT04792489 · EU 2023-508508-39-01